EPW
INDV icon

Evolve Private Wealth’s Indivior Pharmaceuticals INDV Stock Holding History

Evolve Private Wealth’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698K Buy
17,010
+1,286
+8% +$46.7K 0.04% 397
2026
Q1 		$479K Buy
+15,724
New +$519K 0.03% 598

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evolve Private Wealth's INDV Position: Q2 2026 in Review

Evolve Private Wealth increased its Indivior Pharmaceuticals (INDV) stake by 8.2% in Q2 2026, buying an estimated $46.7K and bringing the position to 17,010 shares worth $698K. The position accounts for 0.04% of the portfolio, ranked #397.

Evolve Private Wealth first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Evolve Private Wealth held 17,010 shares of Indivior Pharmaceuticals worth $698K as of Q2 2026.
  • Evolve Private Wealth bought 1,286 Indivior Pharmaceuticals shares in Q2 2026, an estimated $46.7K.
  • Indivior Pharmaceuticals made up 0.04% of Evolve Private Wealth's portfolio in Q2 2026, its #397 holding.
  • Evolve Private Wealth first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.